N303161 N3 Ruling Active

The tariff classification of Imatinib (CAS No. 152459-95-5) and Tofacitinib Citrate (CAS No. 540737-29-9) in bulk powder form, from Italy

Issued March 15, 2019 by U.S. Customs and Border Protection.

Tariff classification

HTS codes: 2933.59.5900, 2933.59.5300

Headings: 2933

Product description

The first product, Imatinib is a tyrosine kinase inhibitor. It is indicated for the treatment of chronic myeloid leukemia and malignant gastrointestinal stromal tumors. The second product, Tofacitinib Citrate belongs to a class of drugs called Janus kinase (JAK) inhibitors. It is indicated for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis and active ulcerative colitis in adults.

CBP rationale

The applicable subheading for the Imatinib in bulk form will be 2933.59.5300, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (…) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other. The applicable subheading for the Tofacitinib Citrate in bulk form will be 2933.59.5900, HTSUS, which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (…) or piperazine ring in the structure: Other: Drugs: Other.

Full text

N303161 March 15, 2019 CLA-2-29:OT:RR:NC:N2:138 CATEGORY: Classification TARIFF NO.: 2933.59.5300; 2933.59.5900 Mr. Gnanapragasam L Jeyaraj SST Corporation 635 Brighton Road Clifton, NJ 07012 RE: The tariff classification of Imatinib (CAS No. 152459-95-5) and Tofacitinib Citrate (CAS No. 540737-29-9) in bulk powder form, from Italy Dear Mr. Jeyaraj: In your letter dated February 21, 2019, you requested a tariff classification ruling. The first product, Imatinib is a tyrosine kinase inhibitor. It is indicated for the treatment of chronic myeloid leukemia and malignant gastrointestinal stromal tumors. The second product, Tofacitinib Citrate belongs to a class of drugs called Janus kinase (JAK) inhibitors. It is indicated for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis and active ulcerative colitis in adults. The applicable subheading for the Imatinib in bulk form will be 2933.59.5300, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (…) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other.” Pursuant to General Note 13, HTS, the rate of duty will be free. The applicable subheading for the Tofacitinib Citrate in bulk form will be 2933.59.5900, HTSUS, which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (…) or piperazine ring in the structure: Other: Drugs: Other.” Pursuant to General Note 13, HTS, the rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on the World Wide Web at https://hts.usitc.gov/current. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at [email protected]. Sincerely, Steven A. Mack Director National Commodity Specialist Division

View original on CBP CROSS →

More rulings on the same tariff codes

N334168 August 15, 2023

The tariff classification of Ensifentrine (CAS No. 1884461-72-6) in bulk powder form, from Portugal

N329297 December 7, 2022

The tariff classification of Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk powder form, from Taiwan

N329037 November 21, 2022

The tariff classification of Trilaciclib Dihydrochloride (CAS No. 1977495-97-8) and Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk form, from Taiwan

N320984 September 7, 2021

The tariff classification of Vibegron (CAS No. 1190389-15-1) in bulk form, from India

N318947 May 14, 2021

The tariff classification of Vericiguat (CAS No. 1350653-20-1) in bulk form and Verquvo® Tablets in dosage form, from Germany

N317830 March 22, 2021

The tariff classification of Sitagliptin Phosphate Monohydrate (CAS No. 654671-77-9) in bulk form, from Spain

N316489 January 12, 2021

The tariff classification of Ozanimod Hydrochloride (CAS No. 1618636-37-5), Brivaracetam (CAS No. 357336-20-0) and Tofacitinib Citrate (CAS No. 540737-29-9) in bulk form, from Taiwan

N308708 January 27, 2020

The tariff classification of Acyclovir (CAS No. 59277-89-3) in bulk form, from Spain

N303158 March 15, 2019

The tariff classification of Bicalutamide (CAS No. 90357-06-5), Linagliptin (CAS No. 668270-12-0) and Aripiprazole (CAS No. 129722-12-9) in bulk powder form, from India

N302078 December 20, 2018

The tariff classification of VITRAKVI™ capsules in dosage form and Larotrectinib (CAS No. 1223403-58-4) in bulk form, from the United States and imported from the United Kingdom

Searching CBP rulings the smart way

TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.

Book a demo →